Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Santoro MM, et al. Among authors: di perri g. Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23343501 Free article.
AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U; AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals. Nasti G, et al. Among authors: di perri g. J Clin Oncol. 2003 Aug 1;21(15):2876-82. doi: 10.1200/JCO.2003.10.162. J Clin Oncol. 2003. PMID: 12885804
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. González de Requena D, et al. Among authors: di perri g. AIDS. 2006 Oct 3;20(15):1977-9. doi: 10.1097/01.aids.0000247121.19951.fa. AIDS. 2006. PMID: 16988521
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, Di Perri G, Filice G, Moroni M, Rizzardini G, Caramello P, Maserati R, Narciso P, Cargnel A, Antinori A, Perno CF; CARe Study Group. Santoro MM, et al. Among authors: di perri g. AIDS Patient Care STDS. 2008 Jan;22(1):7-16. doi: 10.1089/apc.2007.0013. AIDS Patient Care STDS. 2008. PMID: 18095835 Clinical Trial.
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. de Requena DG, et al. Among authors: di perri g, di garbo a. Antimicrob Agents Chemother. 2008 Mar;52(3):1066-71. doi: 10.1128/AAC.01063-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160524 Free PMC article.
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. Among authors: di perri g. J Infect Dis. 2008 May 15;197(10):1408-18. doi: 10.1086/587693. J Infect Dis. 2008. PMID: 18419549
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M. Nicastri E, et al. Among authors: di perri g. Curr HIV Res. 2008 May;6(3):261-6. doi: 10.2174/157016208784325010. Curr HIV Res. 2008. PMID: 18473790
718 results